2025
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker Research 2025, 13: 64. PMID: 40275414, PMCID: PMC12023351, DOI: 10.1186/s40364-025-00780-4.Peer-Reviewed Original ResearchLymphoma-specific survivalOverall survivalCAR-TRelative survivalChimeric antigen receptor T cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaCumulative incidence of deathB-cell lymphomaPopulation-based cohort studyReceipt of chemotherapyIncidence of deathPeriod of diagnosisRefractory DLBCLB symptomsMultivariate survival modelsMedian ageT cellsImproved survivalCumulative incidenceSEER-17Disease courseCohort studyDisease stageFDA approvalTarget Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-Cause MortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination statusLong‐Term Outcomes of Peripheral Artery Disease in Veterans: Analysis of the Peripheral Artery Disease Long‐Term Survival Study (PEARLS)
Girotra S, Li Q, Vaughan‐Sarrazin M, Lund B, Al‐Garadi M, Beckman J, Nathani R, Hoffman R, Chan P, Banerjee S, Tsai S, Kumbhani D, Minniefield‐Young N, Smolderen K, Arya S, Nguyen C, Matheny M, Gobbel G. Long‐Term Outcomes of Peripheral Artery Disease in Veterans: Analysis of the Peripheral Artery Disease Long‐Term Survival Study (PEARLS). Journal Of The American Heart Association 2025, 14: e038403. PMID: 40118806, PMCID: PMC12132885, DOI: 10.1161/jaha.124.038403.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationPeripheral arterial diseaseHealth AdministrationIntegrated health systemOutcomes of peripheral artery diseaseDiagnosis of peripheral arterial diseaseToe-brachial index valuesPrevalence of hypertensionLimb eventsChronic obstructive pulmonary diseaseAnkle-brachial indexImprove careHealth systemObstructive pulmonary diseaseCardiovascular eventsHigh-risk groupNational registryArtery diseaseVeteransIncidence of cardiovascular eventsRegistryIncidence of deathPulmonary diseasePatient yearsStudy end point
2024
Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T. A, Allegretti A, Cullaro G, Ouyang T, Asrani S, Chung R, Przybyszewski E, Wilechansky R, Robinson J, Sharma P, Simonetto D, Jalal P, Orman E, Wadei H, St. Hillien S, Saly D, Ufere N, Dageforde L, Regner K, Belcher J, Patidar K, Consortium F. Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium. Alimentary Pharmacology & Therapeutics 2024, 60: 778-786. PMID: 39010302, PMCID: PMC11349455, DOI: 10.1111/apt.18159.Peer-Reviewed Original ResearchAlcohol-associated hepatitisAcute kidney injuryAcute kidney injury phenotypesHepatorenal syndromeMELD-NaDevelopment of acute kidney injuryCumulative incidence of deathConsecutive adult patientsOutcomes of patientsAlcohol Abuse and Alcoholism (NIAAANon-AH groupRenal replacement therapyPresence of AHAcute tubular necrosisRetrospective cohort studyPredictors of mortalityIncidence of deathAKI stageClinical courseReplacement therapyAdult patientsKidney injuryCumulative incidencePoor prognosisTubular necrosis
2023
2288. Short and Longer-Term All-Cause Mortality among SARS CoV-2-Infected Persons and the Pull-Forward Phenomenon in Qatar
Chemaitelly H, Faust J, Krumholz H, Ayoub H, Abu-Raddad L. 2288. Short and Longer-Term All-Cause Mortality among SARS CoV-2-Infected Persons and the Pull-Forward Phenomenon in Qatar. Open Forum Infectious Diseases 2023, 10: ofad500.1910. PMCID: PMC10676887, DOI: 10.1093/ofid/ofad500.1910.Peer-Reviewed Original ResearchSevere COVID-19Incidence of deathCause mortalityPrimary infectionCOVID-19Primary SARS-CoV-2 infectionSARS-CoV-2-infected personsCox proportional hazards regression modelSARS-CoV-2 infectionProportional hazards regression modelsPrimary infection cohortRetrospective cohort studyCOVID-19 mortalitySARS-CoV-2Short life expectancyCohort studyHazard ratioUnvaccinated personsMonth 3Uninfected personsVaccinated personsControl cohortNational cohortEarly deathCohort
2020
Patterns of oral anticoagulation use with cardioversion in clinical practice
Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart 2020, 107: 642-649. PMID: 32591363, DOI: 10.1136/heartjnl-2019-316315.Peer-Reviewed Original ResearchConceptsStroke/transient ischemic attackVitamin K antagonistsNovel oral anticoagulantsTransient ischemic attackTransoesophageal echocardiogramAtrial fibrillationClinical practiceAtrial Fibrillation IIOral anticoagulation useTime of cardioversionBetter Informed TreatmentMonths of enrollmentIncidence of deathLow-risk procedureSimilar ratesAnticoagulation useIschemic attackMajor bleedingK antagonistsOral anticoagulantsClinical outcomesOutcomes RegistryCardiovascular hospitalisationAF diagnosisInclusion criteriaNonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement
Gryaznov AA, Saeyeldin A, Abdelbaky M, Zafar MA, Tanweer M, Papanikolaou D, Imran M, Li Y, Ziganshin BA, Elefteriades JA. Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement. The American Journal Of Cardiology 2020, 129: 71-78. PMID: 32605717, DOI: 10.1016/j.amjcard.2020.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnticoagulantsAortic ValveAortic Valve InsufficiencyAortic Valve StenosisAspirinAtrial FibrillationBicuspid Aortic Valve DiseaseBioprosthesisCoronary Artery DiseaseFactor Xa InhibitorsFemaleHeart Valve DiseasesHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMortalityPlatelet Aggregation InhibitorsPostoperative CareProportional Hazards ModelsPurinergic P2Y Receptor AntagonistsStrokeThromboembolismWarfarinYoung AdultConceptsAortic valve replacementBiological aortic valve replacementAntithrombotic regimensValve replacementSurgical bioprosthetic aortic valve replacementCox proportional hazards regression modelSurgical aortic valve replacementBioprosthetic aortic valve replacementConsecutive adult patientsCoronary artery diseaseKaplan-Meier analysisIncidence of deathHazards regression modelsAntiplatelet groupAVR patientsRoutine anticoagulationAntithrombotic therapyCardiovascular eventsThromboembolic eventsAdult patientsAdverse eventsAnticoagulation groupArtery diseaseTreatment regimensTherapy group
2019
Outcomes of acute coronary syndrome patients with concurrent extra-cardiac vascular disease in the era of transradial coronary intervention: A retrospective multicenter cohort study
Kodaira M, Sawano M, Kuno T, Numasawa Y, Noma S, Suzuki M, Imaeda S, Ueda I, Fukuda K, Kohsaka S. Outcomes of acute coronary syndrome patients with concurrent extra-cardiac vascular disease in the era of transradial coronary intervention: A retrospective multicenter cohort study. PLOS ONE 2019, 14: e0223215. PMID: 31618228, PMCID: PMC6795465, DOI: 10.1371/journal.pone.0223215.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overCerebrovascular DisordersFemaleHospital MortalityHumansIncidenceMaleMiddle AgedPercutaneous Coronary InterventionPeripheral Vascular DiseasesPostoperative HemorrhageRadial ArteryRegistriesRetrospective StudiesRisk FactorsSeverity of Illness IndexTreatment OutcomeConceptsTransradial coronary interventionAcute coronary syndromePeripheral arterial diseaseCerebrovascular diseaseCoronary interventionVascular diseaseRetrospective multicenter cohort studyAcute coronary syndrome patientsPercutaneous coronary intervention registryMulticenter cohort studyCoronary syndrome patientsCoronary Intervention RegistryIncidence of deathCoronary syndromeCohort studyIntervention RegistryArterial diseaseAdverse outcomesRisk factorsPatient outcomesAccess siteSyndrome patientsHigh riskComplicationsPatientsAntithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Lopes R, Heizer G, Aronson R, Vora A, Massaro T, Mehran R, Goodman S, Windecker S, Darius H, Li J, Averkov O, Bahit M, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey R, Thiele H, Vinereanu D, Granger C, Alexander J. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal Of Medicine 2019, 380: 1509-1524. PMID: 30883055, DOI: 10.1056/nejmoa1817083.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAnticoagulantsAspirinAtrial FibrillationDouble-Blind MethodDrug Therapy, CombinationFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsPyrazolesPyridonesVitamin KConceptsVitamin K antagonistsAcute coronary syndromeClinically relevant nonmajor bleedingP2Y<sub>12</sub> inhibitorsPercutaneous coronary interventionIncidence of ischemic eventsK antagonistsAtrial fibrillationIncidence of deathCoronary syndromeIschemic eventsNonmajor bleedingAntithrombotic regimensVitamin K antagonist groupSecondary outcomesComposite of ischemic eventsApixaban groupPlacebo groupAntithrombotic therapyAspirin groupPrimary outcomeCoronary interventionPatientsRegimensInternational trials
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic eventsAbstract 13615: High-Dose Simvastatin Induce Insulin Resistance During Acute Myocardial Infarction by Inhibiting Intracellular Insulin Signaling, Without Attenuating Its Clinical Benefit
Carvalho L, Moura F, Cintra R, Prada P, Saad M, Coelho O, Sposito A. Abstract 13615: High-Dose Simvastatin Induce Insulin Resistance During Acute Myocardial Infarction by Inhibiting Intracellular Insulin Signaling, Without Attenuating Its Clinical Benefit. Circulation 2015, 132 DOI: 10.1161/circ.132.suppl_3.13615.Peer-Reviewed Original ResearchInsulin sensitivity indexEuglycemic hyperinsulinemic clampMyocardial infarctionPlasma glucoseStress hyperglycemiaLong-term clinical impactAbdominal adipose tissue biopsiesHigh-dose statinsHigh-dose simvastatinDoses of statinsTreated with statinsMeasurement of plasma glucoseInsulin secretionMarker of mortalityST-elevation MIIncidence of deathImpact of hyperglycemiaRisk of deathAdipose tissue biopsiesS80 groupAcute myocardial infarctionIntracellular insulin signalingHigh-doseStatin useClinical benefitMetallic Limus‐Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra‐Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial
Lemos P, Abizaid A, Meireles G, Sarmento-Leite R, Prudente M, Cantarelli M, Dourado A, Mariani J, Perin M, Costantini C, Costa R, Costa J, Chamie D, Campos C, Ribeiro E. Metallic Limus‐Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra‐Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial. Cardiovascular Therapeutics 2015, 33: 367-371. PMID: 26352896, DOI: 10.1111/1755-5922.12159.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedBrazilCardiovascular AgentsCoated Materials, BiocompatibleCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisCoronary VesselsDrug-Eluting StentsFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsSirolimus-eluting stentsLate lumen lossRandomized trialsPrimary endpointLow dose of sirolimusLumen lossIn-stent late lumen lossBiolimus-eluting stentDose of sirolimusAngiographic in-stent late lumen lossOutcomes of patientsAdverse clinical eventsAngiographic late lumen lossDrug-eluting stent formulationsLimus-eluting stentsIncidence of deathClinical eventsClinical comparisonLow dosesStent thrombosisMyocardial infarctionStudy populationStentPatientsTrialsCoronary Computed Tomography Angiography Versus Radionuclide Myocardial Perfusion Imaging in Patients With Chest Pain Admitted to Telemetry: A Randomized Trial.
Levsky J, Spevack D, Travin M, Menegus M, Huang P, Clark E, Kim C, Hirschhorn E, Freeman K, Tobin J, Haramati L. Coronary Computed Tomography Angiography Versus Radionuclide Myocardial Perfusion Imaging in Patients With Chest Pain Admitted to Telemetry: A Randomized Trial. Annals Of Internal Medicine 2015, 163: 174-83. PMID: 26052677, PMCID: PMC4703121, DOI: 10.7326/m14-2948.Peer-Reviewed Original ResearchMeSH KeywordsCardiac CatheterizationChest PainComparative Effectiveness ResearchCoronary AngiographyCoronary Artery DiseaseFemaleFollow-Up StudiesHealth ResourcesHospital UnitsHumansLength of StayMaleMiddle AgedMyocardial Perfusion ImagingMyocardial RevascularizationPatient SatisfactionProspective StudiesRadiation DosageTelemetryTomography, X-Ray ComputedConceptsMyocardial perfusion imagingCCTA groupMPI groupCardiovascular eventsChest painCardiac catheterizationPrimary outcomeRadiation exposurePatient experienceStress myocardial perfusion imagingInner-city medical centerNonfatal cardiovascular eventsOutpatient cardiology visitsAcute chest painMajor cardiovascular eventsIntermediate-term outcomesEmergency department visitsCoronary artery diseaseComparative effectiveness trialIncidence of deathLength of stayAmerican Heart AssociationClinical management decisionsRadionuclide myocardial perfusionLess radiation exposure
2014
Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes An Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy)
Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, Stone GW, Lincoff AM. Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes An Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovascular Interventions 2014, 7: 372-379. PMID: 24630881, DOI: 10.1016/j.jcin.2013.11.017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionComorbidityCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionOdds RatioPercutaneous Coronary InterventionProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSmokingTime FactorsTreatment OutcomeTriageConceptsCoronary artery diseaseMyocardial infarctionACUITY trialMajor bleedingNSTE-ACSArtery diseaseSegment elevation acute coronary syndromesExtent of CADST-segment elevation myocardial infarctionElevation acute coronary syndromeHigh-risk NSTE-ACSSegment Elevation Acute CoronaryDiffuse coronary artery diseaseMyocardial infarction (TIMI) flowAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionPrognosis of patientsPresence of thrombusIncidence of deathLong-term outcomesAcute myocardial infarctionFavorable baseline characteristicsCoronary syndromeNon–ST
2013
Comparison of Transradial Percutaneous Coronary Intervention in Patients with Stable and Unstable Coronary Artery Disease
Ibrahim S, Costa J, Staico R, Siqueira D, Tanajura L, Costa R, Stadler J, Paixão A, Chamié D, Braga S, Feres F, Abizaid A, Sousa A, Sousa J. Comparison of Transradial Percutaneous Coronary Intervention in Patients with Stable and Unstable Coronary Artery Disease. Journal Of Transcatheter Interventions 2013, 21: 246-250. DOI: 10.1016/s2214-1235(15)30139-3.Peer-Reviewed Original ResearchCoronary artery diseasePercutaneous coronary interventionTransradial percutaneous coronary interventionCoronary interventionRetrospective study of patientsIn-hospital outcomes of patientsTertiary hospitalStable coronary artery diseaseTransradial approachCoronary Artery Bypass GraftingOutcomes of patientsStudy of patientsArtery Bypass GraftingIncidence of comorbiditiesIn-Hospital OutcomesIncidence of deathStable CAD groupInstituto Dante Pazzanese de CardiologiaComplex clinical profileCAD groupRetrospective studyClinical profileVascular complicationsBypass GraftingProcedural characteristics
2004
Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease
Shirai K, Lansky AJ, Mehran R, Dangas GD, Costantini CO, Fahy M, Slack S, Mintz GS, Stone GW, Leon MB. Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. The American Journal Of Cardiology 2004, 93: 959-962. PMID: 15081435, DOI: 10.1016/j.amjcard.2003.12.048.Peer-Reviewed Original ResearchConceptsCoronary artery bypassInvasive coronary artery bypassLAD stentingCoronary artery diseaseArtery bypassArtery diseaseClinical outcomesAnterior descending (LAD) coronary artery diseaseConventional coronary artery bypassHigher repeat revascularization ratesQ-wave myocardial infarctionHospital event ratesProximal LAD diseaseRepeat revascularization rateShorter hospital staySubgroup of patientsConventional balloon angioplastyIncidence of deathLong-term efficacyLAD revascularizationMIDCAB groupHospital stayLAD diseaseRevascularization ratesVessel revascularization
2002
Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants
Carlo W, Stark A, Wright L, Tyson J, Papile L, Shankaran S, Donovan E, Oh W, Bauer C, Saha S, Poole W, Stoll B, Network* F. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. The Journal Of Pediatrics 2002, 141: 370-375. PMID: 12219057, DOI: 10.1067/mpd.2002.127507.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasiaVentilation groupVentilator supportExtremely-low-birth-weight infantsExtremely-low-birth-weightMinimal ventilationWeeks postmenstrual ageLong-term outcomesIncidence of deathDexamethasone coursePostmenstrual ageDexamethasone therapyMajor morbiditySaline placeboBirth weightAdverse eventsPrimary outcomeRoutine groupRelative riskRoutine ventilationTreatment groupsWeeksDysplasiaVentilationDexamethasone
2001
Stent Thrombosis in the Modern Era
Cutlip D, Baim D, Ho K, Popma J, Lansky A, Cohen D, Carrozza J, Chauhan M, Rodriguez O, Kuntz R. Stent Thrombosis in the Modern Era. Circulation 2001, 103: 1967-1971. PMID: 11306525, DOI: 10.1161/01.cir.103.15.1967.Peer-Reviewed Original ResearchMeSH KeywordsAspirinBlood Vessel Prosthesis ImplantationCausalityCoronary DiseaseCoronary ThrombosisEndpoint DeterminationFemaleGraft Occlusion, VascularHumansIncidenceLogistic ModelsMaleMiddle AgedMulticenter Studies as TopicMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicSurvival RateTiclopidineTreatment OutcomeConceptsTotal stent lengthStent thrombosisAntiplatelet therapyStent lengthClinical consequencesFinal minimal lumen diameterLumen diameterNative coronary artery lesionsAngiographic stent thrombosisClinical stent thrombosisHigh-pressure deploymentRoutine antiplatelet therapyCoronary artery lesionsIncidence of deathMinimal lumen diameterProcedure-related variablesSecond-generation stentsCoronary stent trialsSerious clinical consequencesFinal lumen diameterNonrandomized registryAntithrombotic regimensArtery lesionsPersistent dissectionMyocardial infarctionLocalized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting
Leon M, Teirstein P, Moses J, Tripuraneni P, Lansky A, Jani S, Wong S, Fish D, Ellis S, Holmes D, Kerieakes D, Kuntz R. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. New England Journal Of Medicine 2001, 344: 250-256. PMID: 11172151, DOI: 10.1056/nejm200101253440402.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryBrachytherapyCombined Modality TherapyCoronary DiseaseCoronary ThrombosisDose-Response Relationship, RadiationDouble-Blind MethodFemaleGamma RaysHumansIridium RadioisotopesMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsRadiotherapy DosageSecondary PreventionStentsConceptsIridium-192 groupMyocardial infarctionLate thrombosisStent restenosisIridium-192Intracoronary irradiationTarget lesionsIntracoronary gamma radiation therapyMajor adverse cardiac eventsFrequency of restenosisOral antiplatelet therapyAdverse cardiac eventsComposite of deathPrimary end pointLate myocardial infarctionIntracoronary radiation therapyIncidence of deathRecurrence of restenosisGamma radiation therapyEligible patientsAngiographic restenosisAntiplatelet therapyPlacebo groupCardiac eventsCoronary angioplasty
2000
Optimally deployed stents in the treatment of restenotic versus de novo lesions
Gruberg L, Hong M, Mintz G, Mehran R, Waksman R, Dangas G, Kent K, Pichard A, Satler L, Lansky A, Kornowski R, Stone G, Leon M. Optimally deployed stents in the treatment of restenotic versus de novo lesions. The American Journal Of Cardiology 2000, 85: 333-337. PMID: 11078302, DOI: 10.1016/s0002-9149(99)00742-0.Peer-Reviewed Original ResearchConceptsDe novo lesionsOptimal stent deploymentTarget lesion revascularizationEvent-free survivalVein graft lesionsNovo lesionsLong-term outcomesMinimal lumen diameterRestenotic lesionsStent deploymentLesion revascularizationGraft lesionsDiabetes mellitusMyocardial infarctionHigh incidenceNon-Q-wave myocardial infarctionDe novo lesions groupFinal minimal lumen diameterLumen diameterSaphenous vein graft lesionsIndependent risk factorDe novo groupIncidence of deathStent deployment techniquesStatistical significant difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply